FHD-286
2 clinical trials
6 abstracts
6 indications
Indication
Advanced Hematologic MalignancyIndication
Acute Myeloid Leukemia (AML)Indication
Acute Myeloid LeukemiaIndication
Myelodysplastic SyndromesIndication
Chronic Myelomonocytic LeukemiaIndication
Uveal MelanomaAbstract
Preclinical efficacy of BRG1/BRM ATPase inhibitor in B lymphoblastic leukemia.Org: Seattle Children's Research Institute, Ben Towne Center for Childhood Cancer Research,
Clinical trial
A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy or Combination Therapy, in Subjects With Advanced Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286 in Subjects With Metastatic Uveal MelanomaStatus: Terminated, Estimated PCD: 2023-11-30
Abstract
Korean Precision Medicine Networking Group study of molecular profiling guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) II (KCSG AL 22-09).Org: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, Seoul National University Hospital, Jongno-Gu, South Korea, Korea University Anam Hospital, Seoul, South Korea, Samsung Medical Center, Seoul, South Korea,
Abstract
Germline mutations in hereditary renal cell carcinoma (RCC) genes among 32,240 patients with all cancer types.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell College of Medicine, Weill Medical College,
Abstract
Frequency of pathogenic germline variants in cancer susceptibility genes in 841 renal cell carcinoma cases.Org: AcornMed Biotechnology Co., Ltd., Beijing, China,
Abstract
Genetic testing outcomes and pathogenic germline mutation prevalence in renal cell carcinoma.Org: Rogel Comprehensive Cancer Center, University of Michigan, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Division of Metabolism, Endocrinology, and Diabetes,
Abstract
Prospective prevalence estimation of BRCA1, BRCA2, and other germline mutations associated with hereditary pancreatic cancer (HPC) using a comprehensive gene panel in an unselected cohort of Mexican patients with pancreatic ductal adenocarcinoma (PDAC).Org: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Instituto Nacional de Cancerologia, Instituto Nacional de Medicina Genómica, Facultad de Medicina del Hospital Universitario, Universidad Autónoma de Nuevo León, Monterrey, NL, Mexico,